SAMe for Health & Longevity - Quick Reference Sheet

SAMe for Health & Longevity

Created on 08/13/2026 – Quick Reference based on Evidence Review created using AI4L / Grok 4.5 Audit

Laboratory-made SAMe is used for mood, joints, and liver function. Mood and joint signals are real but contested; liver tests improve more consistently than survival. Gastrointestinal upset is common and usually mild. The distinctive harm is a mania switch in bipolar-spectrum illness. It is not used with antidepressant drugs that block monoamine oxidase. Not a general longevity drug. (Full Review)

Protocol

Depression-range oral protocol
800–1,600 mg/day
Enteric-coated, often split; joint-range 1,200 mg/day; liver-range 1,000–1,200 mg/day
Time of day
Morning and early afternoon
About 30 minutes before meals on an empty stomach
Split versus single dose
Split doses
Matches the short half-life and the tablet load at 1,200–1,600 mg
Time to effect
Mood
1–2 weeks
Some separation by week 1–2
Joints
By month 2
Slower than celecoxib; similar by month 2
Liver enzymes
Weeks to months
Laboratory improvement more consistent than survival

Benefits

Contraindications
  • Bipolar I or II, or any prior antidepressant-induced mania or hypomania
  • Concurrent MAOI (monoamine oxidase inhibitor) therapy
  • Parkinson's disease treated with levodopa without specialist co-management
  • Advanced immunocompromise (untreated HIV with CD4 below 200 cells/µL) without specialist co-management
  • Pregnancy outside a dedicated obstetric cholestasis protocol
  • Known hypersensitivity to SAMe tosylate, butanedisulfonate, or tablet excipients
Key Interactions
  • SSRIs and SNRIs (serotonin-norepinephrine reuptake inhibitors; sertraline, escitalopram, venlafaxine)
  • Tricyclic antidepressants (imipramine, amitriptyline)
  • Tramadol, triptans, St. John's wort, 5-hydroxytryptophan, L-tryptophan
  • Antipsychotics (olanzapine, risperidone) and amphetamines (lisdexamfetamine)
  • Dextromethorphan
  • Levodopa
  • Over-the-counter NSAIDs (ibuprofen, naproxen)
  • Folate, vitamin B12, and vitamin B6
  • 5-methyltetrahydrofolate

Risk & Side Effects

  • High: Manic or hypomanic mood switch; gastrointestinal intolerance
  • Medium: Anxiety, insomnia, and agitation; serotonergic toxicity with antidepressants
  • Low: Reduced levodopa effect; Pneumocystis infection in immunocompromised people
  • Speculative: Excess methylation via adenine

Monitoring

Marker Target Why
Homocysteine <8 µmol/L Tracks whether donated methyl groups are being recycled
Vitamin B12 500–1,000 pg/mL Cofactor for methionine synthase
Folate (red-cell) Upper half of the laboratory range Substrate for remethylation to methionine
ALT / AST Low-normal (often <25–30 U/L) Liver response and safety
Total bilirubin Within the laboratory range, falling if cholestatic Bile-flow response
Mood score (PHQ-9 or equivalent) No established target; track improvement from the person's own baseline Detects benefit and activation

Cadence: Baseline bipolar-spectrum history plus B12, folate, homocysteine, ALT, AST, and bilirubin; 2 weeks mood and sleep only; 4–8 weeks symptoms plus labs if liver use; then every 3 months in year 1 and every 6–12 months thereafter

Qualitative Assessment

  • Sleep onset and nighttime awakenings after afternoon doses
  • Irritability, racing thoughts, or unusually elevated mood
  • Joint stiffness on waking and pain during usual training
  • Energy and cognitive clarity across the day
  • Nausea, loose stool, or abdominal cramping after tablets